New drug HRS-7535 shows promise for diabetic kidney disease in phase 2 trial
NCT ID NCT06415214
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 23 times
Summary
This study tested a new medicine called HRS-7535 in 281 adults with type 2 diabetes who also have kidney disease. The goal was to see if the drug can improve kidney function and control blood sugar over 16 weeks. Participants took either the drug or a placebo, and researchers measured changes in urine protein and other health markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.